Jasper Therapeutics, Inc.
JSPR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$0.51
KIRA · Stoqly’s AI analyst, in plain words
- Jasper Therapeutics, Inc. lost $75.8M in fiscal 2025.
Market cap
$14.5M
P/E
—
Revenue
—
Net income
−$75.8M
Free cash flow
—
Operating margin
—
Jasper Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$75.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Jasper Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Jasper Therapeutics, Inc.
- CIK
- 0001788028
Jasper Therapeutics, Inc. · JSPR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.1M | −$0.1M | −$0.2M | — | — |
| Net interest income | −$0.1M | −$0.1M | −$0.2M | — | — |
| Operating margin | 46,041.3% | 44,518.3% | 27,992.3% | — | — |
| Net income | −$30.6M | −$37.7M | −$64.5M | −$71.3M | −$75.8M |
| Net margin | 38,296.3% | 32,769.6% | 26,205.3% | — | — |
| Diluted EPS | −$2.69 | −$10.33 | −$6.18 | −$4.89 | −$3.95 |
| Cash | |||||
| Cash from operations | −$33.7M | −$45.9M | −$52.1M | −$62.6M | −$77.2M |
| Share count change | 86.0% | −68.0% | 186.1% | 39.7% | 31.4% |
| Debt and strength | |||||
| Cash and short-term investments | $84.7M | $38.3M | $86.9M | $71.6M | $28.7M |
| Shareholders' equity | $69.5M | $36.0M | $78.4M | $61.7M | $4.2M |
| Current ratio | 11.0x | 5.9x | 7.2x | 5.0x | 2.6x |
| Returns and quality | |||||
| Return on equity | −178.2% | −71.4% | −112.7% | −101.7% | −230.3% |
| Return on tangible equity | −44.1% | −104.7% | −82.2% | −115.6% | −1,826.1% |
| Piotroski F-score | 3 | 1 | 3 | — | — |
| Altman Z'' | 3.6 | −6.4 | −0.4 | −7.7 | −40.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Jasper Therapeutics, Inc. · JSPR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.51 a share, the company is worth $14.5M.
Source: SEC EDGAR XBRL filings (CIK 0001788028). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.